These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 29610456)
21. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. Wasserkort R; Kalmar A; Valcz G; Spisak S; Krispin M; Toth K; Tulassay Z; Sledziewski AZ; Molnar B BMC Cancer; 2013 Aug; 13():398. PubMed ID: 23988185 [TBL] [Abstract][Full Text] [Related]
22. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. Tóth K; Wasserkort R; Sipos F; Kalmár A; Wichmann B; Leiszter K; Valcz G; Juhász M; Miheller P; Patai ÁV; Tulassay Z; Molnár B PLoS One; 2014; 9(12):e115415. PubMed ID: 25526039 [TBL] [Abstract][Full Text] [Related]
23. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Liu Y; Tham CK; Ong SY; Ho KS; Lim JF; Chew MH; Lim CK; Zhao Y; Tang CL; Eu KW Biomarkers; 2013 Aug; 18(5):399-405. PubMed ID: 23862763 [TBL] [Abstract][Full Text] [Related]
24. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study. Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049 [TBL] [Abstract][Full Text] [Related]
25. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595 [TBL] [Abstract][Full Text] [Related]
26. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker. Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373 [TBL] [Abstract][Full Text] [Related]
27. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer. Song L; Li Y Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083 [TBL] [Abstract][Full Text] [Related]
28. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641 [TBL] [Abstract][Full Text] [Related]
29. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215 [TBL] [Abstract][Full Text] [Related]
30. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Ladabaum U; Allen J; Wandell M; Ramsey S Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793 [TBL] [Abstract][Full Text] [Related]
31. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL; BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170 [TBL] [Abstract][Full Text] [Related]
32. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Song L; Jia J; Peng X; Xiao W; Li Y Sci Rep; 2017 Jun; 7(1):3032. PubMed ID: 28596563 [TBL] [Abstract][Full Text] [Related]
33. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. Song L; Yu H; Jia J; Li Y Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742 [TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257 [TBL] [Abstract][Full Text] [Related]
35. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221 [TBL] [Abstract][Full Text] [Related]
36. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients. Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516 [TBL] [Abstract][Full Text] [Related]
37. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298 [TBL] [Abstract][Full Text] [Related]
38. Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population. Lima AB; Dos Reis MB; Matsushita M; Dos Reis MT; de Oliveira MA; Reis RM; Guimarães DP Cancer Med; 2023 Aug; 12(15):15854-15867. PubMed ID: 37338022 [TBL] [Abstract][Full Text] [Related]
39. Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer. Ma ZY; Chan CSY; Lau KS; Ng L; Cheng YY; Leung WK Sci Rep; 2021 Dec; 11(1):23446. PubMed ID: 34873218 [TBL] [Abstract][Full Text] [Related]
40. Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis. Sun G; Meng J; Duan H; Zhang D; Tang Y Pathol Oncol Res; 2019 Oct; 25(4):1525-1534. PubMed ID: 30488278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]